Belmont Capital LLC Invests $36,000 in Amgen, Inc. (NASDAQ:AMGN)
Belmont Capital LLC purchased a new position in Amgen, Inc. (NASDAQ:AMGN) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 150 shares of the medical research company’s stock, valued at approximately $36,000. Amgen accounts for approximately 0.0% of Belmont Capital LLC’s investment portfolio, making the stock its 23rd biggest position.
Other institutional investors and hedge funds also recently modified their holdings of the company. Private Advisor Group LLC boosted its position in shares of Amgen by 4.0% in the 2nd quarter. Private Advisor Group LLC now owns 38,488 shares of the medical research company’s stock worth $7,093,000 after purchasing an additional 1,494 shares in the last quarter. Greylin Investment Mangement Inc. lifted its position in Amgen by 25.0% in the 2nd quarter. Greylin Investment Mangement Inc. now owns 15,912 shares of the medical research company’s stock valued at $2,932,000 after acquiring an additional 3,180 shares in the last quarter. Tibra Equities Europe Ltd lifted its position in Amgen by 62.8% in the 3rd quarter. Tibra Equities Europe Ltd now owns 19,700 shares of the medical research company’s stock valued at $3,812,000 after acquiring an additional 7,600 shares in the last quarter. Daiwa Securities Group Inc. lifted its position in Amgen by 0.7% in the 3rd quarter. Daiwa Securities Group Inc. now owns 38,048 shares of the medical research company’s stock valued at $7,362,000 after acquiring an additional 258 shares in the last quarter. Finally, Lowe Brockenbrough & Co. Inc. lifted its position in Amgen by 0.5% in the 3rd quarter. Lowe Brockenbrough & Co. Inc. now owns 30,380 shares of the medical research company’s stock valued at $5,879,000 after acquiring an additional 155 shares in the last quarter. 76.58% of the stock is currently owned by hedge funds and other institutional investors.
AMGN traded up $2.99 during mid-day trading on Tuesday, reaching $239.91. 1,316,533 shares of the company traded hands, compared to its average volume of 1,809,933. The stock has a market capitalization of $141.57 billion, a P/E ratio of 16.66, a P/E/G ratio of 2.07 and a beta of 1.11. The company has a quick ratio of 2.59, a current ratio of 2.89 and a debt-to-equity ratio of 2.54. The company’s fifty day moving average price is $238.06 and its 200-day moving average price is $208.24. Amgen, Inc. has a 52-week low of $166.30 and a 52-week high of $244.99.
The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 14th will be paid a dividend of $1.60 per share. The ex-dividend date of this dividend is Thursday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $1.45. This represents a $6.40 dividend on an annualized basis and a yield of 2.67%. Amgen’s payout ratio is currently 40.28%.
AMGN has been the topic of several analyst reports. Argus upped their price objective on Amgen from $240.00 to $265.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Mizuho reaffirmed a “hold” rating and issued a $212.00 price objective on shares of Amgen in a research report on Sunday, September 29th. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Amgen in a research report on Monday, September 30th. Bank of America initiated coverage on Amgen in a research report on Wednesday, October 16th. They issued a “neutral” rating and a $215.00 price objective on the stock. Finally, BMO Capital Markets upped their price objective on Amgen from $240.00 to $275.00 and gave the company an “outperform” rating in a research report on Thursday, January 9th. Eleven research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Amgen currently has a consensus rating of “Buy” and a consensus target price of $235.39.
In other news, Director R Sanders Williams sold 425 shares of the company’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $215.45, for a total value of $91,566.25. Following the completion of the sale, the director now directly owns 5,413 shares in the company, valued at approximately $1,166,230.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jonathan P. Graham sold 9,000 shares of the company’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $230.54, for a total value of $2,074,860.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,162 shares of company stock valued at $4,214,030. Company insiders own 0.25% of the company’s stock.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Featured Article: Google Finance Portfolio
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.